Cipla Ltd is one of the leading pharmaceutical company in India.

The company focuses on

development of new formulations and has a wide range of pharmaceutical products.
The product portfolio includes over 1,500 products across wide range of therapeutic
categories. The company’s business is divided into three strategic units - APIs, respiratory
and Cipla Global Access. Cipla companies largest market is India, followed by Africa and
North America. Cipla sells active pharmaceutical ingredients to other manufacturers as well
as pharmaceutical and personal care
products,including Escitalopram (antidepressant), Lamivudine and Fluticasone propionate.
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80
countries.

Shareholding Pattern - Cipla Ltd.

Holder's Name No of Shares % Share Holding

NoOfShares 806463279 100%

Promoters 120767784 14.97%

ForeignInstitutions 187211530 23.21%

NBanksMutualFunds 117825645 14.61%

Others 53132022 6.59%

GeneralPublic 130782419 16.22%

FinancialInstitutions 20459535 2.54%

ForeignPromoter 174907187 21.69%

GDR 1377157 0.17%

Board Of Directors Name Designation Dr.Y K Hamied Chairman Ms.Samina Hamied

Executive Vice Chairman Dr.Peter Mugyenyi Independent Director Ms.Punita Lal
Independent Director Mr.Adil Zainulbhai Independent Director Mr.Ashok Sinha
Independent Director Ms.Naina Lal Kidwai Independent Director Mr.Umang Vohra
Managing Director & Global CEO Mr.S Radhakrishnan Non Exe.Non Ind.Director
Mr.M K Hamied Vice Chairman Key Executives Name Designation Mr.Rajendra
Chopra Co. Secretary & Compl. Officer Mr.Kedar Upadhye Global Chief Financial
Officer Dr.Raju Mistry Global Chief People Officer Ms.Geena Malhotra Global Chief
Technology Officer Dr.Ranjana Pathak Global Head Mr.Swapn Malpani Global Head

Read more at: https://www.goodreturns.in/company/cipla/management-team.html

SWOT Analysis of Cipla Limited –

SWOT Analysis of Cipla [Detailed]
SWOT Analysis of Cipla Limited focuses on Strengths,
weaknesses, opportunities, and threats. Strength and Weakness
are internal factors and Opportunities and Threats are the
external factors that influence the SWOT Analysis of Cipla
Limited. Cipla Limited has a strong employee base of 22036
employees. The total Assets of Cipla Limited are 3.3 Billion US
Dollars. The revenue of Cipla Limited is 2.5 Billion US Dollars.
Cipla Limited is a pharmaceutical company that develops and
sells prescription medications, active pharmaceutical ingredients
(API), and veterinary medicines. The company’s headquarters
are in Mumbai, India, and it has extensive R&D and production
facilities there.
Page Contents
Strength in the SWOT Analysis of Cipla Limited –
SWOT Analysis of Cipla Limited
 Product Portfolio: Cipla offers a diverse product portfolio
that includes APIs and formulations for human and animal
 healthcare goods. Cipla offers over 2000 items in over 65
categories and is always trying to expand its product line.
 Low-Cost Drugs for Cancer Patients: Cipla offers and
supports cancer patients by offering low-cost drugs, and it
also developed a “No Touch Breast Scan” which is a stride
ahead in screening technology in India.
 Robust Research and Development: Cipla has prioritized
the development of new drugs, as well as the improvement
of medication delivery technologies and the expansion of
product uses. Cipla has established a robust Research &
Development infrastructure for this purpose. Cipla’s strong
R&D facilities are strongly backed by several industrial
enterprises.
 High Recognized: Cipla’s products are highly recognized by
regulatory agencies in India, the United States, Germany,
and the United Kingdom, among others, lending legitimacy
to the company’s products.
 Strong Brand Portfolio: Over the years, Cipla has made
significant investments in developing a strong brand
portfolio. This is reinforced by Cipla SWOT analysis. If the
company wishes to grow into other product categories, this
brand portfolio may be quite beneficial.
 Good Training Programmes: Successful training
programmes have resulted in a highly competent
workforce. Cipla has invested heavily in employee training
and development, resulting in a team that is not just highly
competent but also driven to achieve more.

Must Read  SWOT Analysis of ASUS - ASUS SWOT Analysis [Explained]

Weaknesses in the SWOT Analysis of Cipla Limited

– SWOT Analysis of Cipla Limited
  Rivalry: High rivalry from both domestic and global
pharmaceutical businesses restricts Cipla’s market share
and prevents rapid expansion.
 Dependent on Indian Market: Cipla’s primary revenue-
generating market in India. Although Cipla has a presence
in over 100 other countries, it has little clout in other
developed markets and is thus heavily reliant on the Indian
market.
Opportunities in the SWOT Analysis of Cipla Limited
– SWOT Analysis of Cipla Limited
 Expansion: Cipla is continuously expanding its business in
India and internationally through efforts such as
investments, collaborations, and acquisitions. Cipla, for
example, invested in a biotech manufacturing facility in
South Africa. Cipla has also acquired InvaGen
Pharmaceuticals in the United States, among other things.
 Treatment: Cipla, via C-GA, provides a comprehensive
variety of ARV medications for the treatment of HIV/AIDS in
both children and adults. Cipla’s medicines have the
potential to treat an increasing number of people.
 Develop in Emerging Countries: Cipla could look forward
to expanding in emerging markets, particularly in countries
where medical infrastructure is developing and, as a result,
pharmaceutical is likely to grow.
Threats in the SWOT Analysis of Cipla Limited –
SWOT Analysis of Cipla Limited
 Regulation: Governments have influence over drug prices
through national health organizations. A new pricing
strategy under Drug price regulation has been suggested in
India, which might have a severe influence on the sector.
Pricing policy changes have an impact on pharmaceutical
firms.
 Intense Competition: Major companies like Sun Pharma,
Cadila, Lupin, and others are fiercely competing in the
 Indian generics sector. This has an impact on Cipla’s growth
potential as well as its market share.
 Exchange rate fluctuations: Any variations in exchange
rates influence the company’s financial agreements with
other nations, which might have an impact on profitability.
 Competition from Generic Medicines: Generic Medicines
are giving tough competition to Cipla Limited.
 Change in Technology: Technological Changes can reduce
the production cost. If another company uses the latest
technology it can give tough competition to Cipla.